Genomtec S.A. Logo

Genomtec S.A.

Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.

GMT | WAR

Overview

Corporate Details

ISIN(s):
PLGNMTC00017
LEI:
259400ND13Y44ADMG554
Country:
Poland
Address:
WROCŁAW BIERUTOWSKA 57-59, 51-317 WROCŁAW
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genomtec S.A. is a medical technology company specializing in the research, development, and commercialization of innovative molecular diagnostic solutions. The company's flagship product is the Genomtec ID, a mobile platform designed for rapid and precise genetic diagnostics at the point-of-care. Its core technology is based on proprietary isothermal nucleic acid amplification methods. A key commercialized product is the CE-IVD certified GenomtecID Respiratory Panel 5-Plex, which detects viruses and bacteria responsible for respiratory tract infections. The company is also advancing its OncoSNAAT project in the field of genomics.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 18:10
Audit Report / Information
zal04_opinia_RN_do_stanowiska.pdf
Polish 154.5 KB
2025-09-29 18:10
Audit Report / Information
zal05_Stanowisko_Zarzadu_do_zastrzezenia.pdf
Polish 144.6 KB
2025-09-29 18:10
Management Discussion and Analysis
zal03_genomtec_sprawozdanie_zarzadu_ip_2025_vfinal_signed_1.pdf
Polish 1.1 MB
2025-09-29 18:10
Audit Report / Information
zal02_GENOMTEC_PSF_2025_MSR_Raport_z_przegladu_ost.pdf
Polish 420.3 KB
2025-09-29 18:10
Interim Report
zal01_genomtec_sf_06.2025_sig_signed.pdf
Polish 1.6 MB
2025-09-25 17:13
Regulatory News Service
Otrzymanie od Europejskiego Urzędu Patentowego decyzji o udzieleniu patentu eur…
Polish 1.6 KB
2025-09-15 17:12
Regulatory News Service
Otrzymanie od Urzędu Patentowego w Japonii decyzji o udzieleniu ochrony patento…
Polish 2.0 KB
2025-09-15 17:08
Share Issue/Capital Change
Podjęcie przez Zarząd Giełdy Papierów Wartościowych uchwały w sprawie dopuszcze…
Polish 1.0 KB
2025-09-11 17:57
Share Issue/Capital Change
Przyznanie akcji w ramach warunkowego podwyższenia kapitału zakładowegoPrzyznan…
Polish 2.3 KB
2025-08-14 17:28
Share Issue/Capital Change
Przyznanie akcji w ramach warunkowego podwyższenia kapitału zakładowego - Conte…
Polish 2.2 KB
2025-08-01 15:26
Regulatory News Service
Otrzymanie od Urzędu Patentowego w Japonii decyzji o udzieleniu ochrony patento…
Polish 1.7 KB
2025-07-31 10:13
Board/Management Information
Powołanie nowego Członka Zarządu GENOMTEC S.A. - Content (PL)
Polish 2.7 KB
2025-07-11 20:04
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym…
Polish 1.0 KB
2025-07-11 20:00
Post-Annual General Meeting Information
zal01_GENOMTEC_ESPI_32_2025_Zalacznik..pdf
Polish 129.4 KB
2025-07-11 20:00
Post-Annual General Meeting Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie Genomtec S.A. w dn…
Polish 627 bytes

Automate Your Workflow. Get a real-time feed of all Genomtec S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Genomtec S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.